Klinische Endpunkte in Real-World-Register-Studien

Hartkopf AD, Emons J, Lux MP, Taran FA, Overkamp F, Tesch H, Titzmann A, Pöschke P, Lüftner D, Wallwiener M, Müller V, Beckmann M, Belleville E, Janni W, Fehm TN, Kolberg HC, Ettl J, Wallwiener D, Schneeweiss A, Brucker SY, Fasching P (2020)

Publication Type: Journal article, Review article

Publication year: 2020

Journal

DOI: 10.1007/s00761-020-00766-x

Abstract

Background: The therapeutic options for the individual patient with metastatic breast cancer are becoming more and more specific. Evidence for therapeutic recommendations from clinical trials is not available for all treatment situations and patient subgroups. This makes the collection and evaluation of real-world data meaningful. Methods and aims: To provide recommendations for up-to-date treatments and participation in clinical trials for patients with metastatic breast cancer, the Prospective Academic Translational Research Network (PREAGNANT) has been established to optimize the oncological quality of care in the advanced therapeutic setting. The main aim is to systematically record medical care of patients with metastatic breast cancer in real life including the therapeutic effects and side effects of the different treatment strategies, to monitor the quality of life changes during therapy, to identify patients who could participate in a clinical drug study and to enable a targeted therapy based on molecular structures of breast cancer patients. Conclusion: This article presents a summary of the PRAEGNANT network and sheds light on the question of the portability of the various endpoints from clinical trials into the real world treatment situation.

Authors with CRIS profile

Involved external institutions

Marienhospital Bottrop Germany (DE) OncoConsult Germany (DE) Ruprecht-Karls-Universität Heidelberg Germany (DE) Eberhard Karls Universität Tübingen Germany (DE) Klinikum rechts der Isar Germany (DE) Universitätsklinikum Ulm Germany (DE) Charité - Universitätsmedizin Berlin Germany (DE) ClinSol GmbH & Co.KG Germany (DE) Universitätsklinikum Heidelberg Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) Germany (DE) Universitätsspital Zürich (USZ) Switzerland (CH) Universitätsklinikum Düsseldorf Germany (DE) St. Vincenz-Krankenhaus Germany (DE) Agaplesion Markus Krankenhaus Germany (DE)

How to cite

APA:

Hartkopf, A.D., Emons, J., Lux, M.P., Taran, F.A., Overkamp, F., Tesch, H.,... Fasching, P. (2020). Klinische Endpunkte in Real-World-Register-Studien. Onkologe. https://doi.org/10.1007/s00761-020-00766-x

MLA:

Hartkopf, Andreas D., et al. "Klinische Endpunkte in Real-World-Register-Studien." Onkologe (2020).

BibTeX: Download